US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer’s Disease: Implications for Global Drug Development
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer’s Disease: Implications for Global Drug Development
Authors
Keywords
-
Journal
CTS-Clinical and Translational Science
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-02-11
DOI
10.1111/cts.12755
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lowering of Amyloid-Beta by β-Secretase Inhibitors — Some Informative Failures
- (2019) David S. Knopman NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease
- (2019) Michael F. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan
- (2019) Sumimasa Nagai INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
- (2018) Clifford R. Jack et al. Alzheimers & Dementia
- Expediting drug development for serious illness: Trade-offs between patient access and certainty
- (2018) Janet Woodcock Clinical Trials
- Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
- (2018) John E. Harrison Alzheimers Research & Therapy
- On the path to 2025: understanding the Alzheimer’s disease continuum
- (2017) Paul S. Aisen et al. Alzheimers Research & Therapy
- Regulatory watch: Challenges in drug development for central nervous system disorders: a European Medicines Agency perspective
- (2016) Florence Butlen-Ducuing et al. NATURE REVIEWS DRUG DISCOVERY
- Building a roadmap for developing combination therapies for Alzheimer’s disease
- (2015) Daniel Perry et al. Expert Review of Neurotherapeutics
- Building a roadmap for developing combination therapies for Alzheimer’s disease
- (2015) Daniel Perry et al. Expert Review of Neurotherapeutics
- Harmonized diagnostic criteria for Alzheimer's disease: recommendations
- (2014) J. C. Morris et al. JOURNAL OF INTERNAL MEDICINE
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
- (2014) Bruno Dubois et al. LANCET NEUROLOGY
- Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Clifford R. Jack et al. Alzheimers & Dementia
- Editorial: New drugs for Alzheimer's disease in Japan
- (2011) Masatoshi Takeda et al. PSYCHIATRY AND CLINICAL NEUROSCIENCES
- We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer’s disease drug development
- (2007) Rachelle S. Doody Alzheimers & Dementia
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started